KariElizabethSufficoolMD
Pathology • Chesterfield, MODermatopathology
Dermatopathologist United Skin Specialists
Dr. Sufficool is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1001 Chesterfield Pkwy E
Chesterfield, MO 63017Phone+1 763-317-1580Fax+1 952-473-7281
Summary
- Board certified in Anatomic and Clinical Pathology with subspecialty board certification in Dermatopathology. Missouri and Illinois medical licenses.
Education & Training
SSM Health/Saint Louis University School of MedicineFellowship, Dermatopathology, 2015 - 2016
Washington University/B-JH/SLCH ConsortiumResidency, Pathology-Anatomic and Clinical, 2011 - 2015
University of Nebraska College of MedicineClass of 2011
Certifications & Licensure
IL State Medical License 2021 - 2026
MO State Medical License 2015 - 2026
MN State Medical License 2024 - 2025- American Board of Pathology Pathology - Anatomic/Pathology - Clinical
- American Board of Pathology Dermatopathology
Awards, Honors, & Recognition
- Fellow (FASDP) American Society of Dermatopathology
- Alpha Omega Alpha (AOA) Honor Society Washington University Chapter, Saint Louis, Missouri, 2015
- Physician-In-Training Award American Society of Dermatopathology (ASDP), 2014
- Join now to see all
Publications & Presentations
PubMed
- 4 citationsDermatopathologist assessment of "pathologist-to-dermatologist" communication for dermatopathology services.Umar A. Sheikh, Kari E. Sufficool, Paula Buchanan, Eric S. Armbrecht, Nicole M. Burkemper
Journal of Cutaneous Pathology. 2020-04-01 - Erythematous papules on the scrotum, trunk, and extremities.Kavita Darji, Erin E. Williams, Kari E. Sufficool, Maria Yadira Hurley
Cutis. 2019-10-01 - 3 citationsImmunophenotype Expression Change From CD52+ to CD52- on Erythrodermic Peripheral T-cell Lymphoma, Not Otherwise Specified After Treatment With Alemtuzumab.Maulik M. Dhandha, Kari E. Sufficool, Claudia I. Vidal, Katherine Robbins, Mark Fesler
The American Journal of Dermatopathology. 2017-09-01
Other Languages
- Spanish
External Links
- United Skin Specialistshttps://unitedskinspecialists.com/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
